Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development

Published: Jan 29, 2020 | Tags: Roche, Collaborate, Cambridge Quantum Computing, Develop, Quantum Algorithm, Drug, Discovery, Development

Janssen Reports Results of Amivantamab in P-I CHRYSALIS Study for Metastatic or Unresectable NSCLC and EGFR Exon 20 Insertion Mutations

Published: Jan 29, 2020 | Tags: Janssen, Reports, Results, Amivantamab, P-I, CHRYSALIS, Study,  Metastatic, Unresectable, NSCLC, EGFR, Exon 20, Insertion, Mutations

Lilly Signs a License Agreement with Asahi Kasei Pharma for AK1780 to Treat Chronic Pain

Published: Jan 29, 2020 | Tags: Lilly, Signs, License, Agreement, Asahi Kasei Pharma, AK1780, Treat, Chronic Pain

Bio-Thera Solutions Reports the US FDA's Acceptance of BLA for BAT1706 (Proposed Biosimilar to Avastin)

Published: Jan 29, 2020 | Tags: Bio-Thera Solutions, Reports, US, FDA, Acceptance, BLA, BAT1706, (Proposed Biosimilar to Avastin)

Amgen Report Results of Sotorasib in P-II Study for KRAS G12C-Mutated Advanced NSCLC

Published: Jan 29, 2020 | Tags: Amgen, Report, Results, Sotorasib, P-II, Study, KRAS G12C, Mutated, Advanced, NSCLC

Merck Signs an Exclusive Worldwide License Agreement with Artiva to Develop CAR-NK Cell Therapies

Published: Jan 29, 2020 | Tags: Merck, Signs, Exclusive, Worldwide, License, Agreement, Artiva, Develop, CAR-NK Cell, Therapies

BioInvent Report Results of BI-1206 + Rituximab in P- I/IIa Study for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Published: Jan 28, 2020 | Tags: BioInvent, Report, Results, BI-1206, Rituximab, P- I/IIa, Study,  Relapsed, Refractory, B-cell, Non-Hodgkin's, Lymphoma

ImaginAb Signs a Multi-Year Non-Exclusive License Agreement with Neuvogen for CD8 ImmunoPET Technology

Published: Jan 28, 2020 | Tags: ImaginAb, Signs, Multi-Year, Non-Exclusive, License, Agreement,  Neuvogen, CD8, ImmunoPET, Technology

Regeneron's REGEN-COV Antibody Cocktail Confirms its Effectiveness Against UK and South Africa SARS-CoV-2 Variants

Published: Jan 28, 2020 | Tags: Regeneron, REGEN-COV, Antibody, Cocktail, Confirms, Effectiveness, Against, UK, South Africa, SARS-CoV-2, Variants

Pfizer's Xeljanz (tofacitinib) Fails to Meet its Co-Primary Endpoint in ORAL Surveillance Safety Study

Published: Jan 28, 2020 | Tags: Pfizer, Xeljanz (tofacitinib), Fails, Meet, Co-Primary, Endpoint, ORAL, Surveillance, Safety, Study

AstraZeneca Selects AI-Generated CKD Target Under its Collaboration with BenevolentAI

Published: Jan 28, 2020 | Tags: AstraZeneca, Selects, AI-Generated, CKD, Target, Collaboration, BenevolentAI

Eli Lilly Collaborates with GSK and VIR to Evaluate Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

Published: Jan 28, 2020 | Tags: Eli Lilly, Collaborates, GSK, VIR, Evaluate, Bamlanivimab (LY-CoV555), VIR-7831 (GSK4182136), COVID-19

Abbott's Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening

Published: Jan 27, 2020 | Tags: Abbott, Panbio, Rapid, Antigen Test, Receives, CE, Mark, Mass, COVID-19, Screening

AbbVie's Rinvoq (upadacitinib) Receives the EC's Approval for Psoriatic Arthritis and Ankylosing Spondylitis

Published: Jan 27, 2020 | Tags: AbbVie, Rinvoq (upadacitinib), Receives, EC, Approval, Psoriatic Arthritis, Ankylosing Spondylitis

Regeneron Reports Results of REGEN-COV Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19

Published: Jan 27, 2020 | Tags: Regeneron, Reports, Results, REGEN-COV, Antibody, Cocktail, Passive, Vaccine, Prevent, COVID-19

Shionogi Concludes a License Agreement with BioAge for BGE-175 to Control the Aggravation of COVID-19

Published: Jan 27, 2020 | Tags: Shionogi, Concludes, License, Agreement, BioAge, BGE-175, Control, Aggravation, COVID-19

Eli Lilly and AbCellera Report Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV16) in P-II/III BLAZE-1 Study for Preventing COVID-19

Published: Jan 27, 2020 | Tags: Eli Lilly, AbCellera, Report, Results, Bamlanivimab (LY-CoV555), Etesevimab (LY-CoV16), P-II/III, BLAZE-1, Study, Preventing, COVID-19

Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer

Published: Jan 27, 2020 | Tags: Merck, Keytruda (pembrolizumab), Receives, EC, Approval, 1L, Treatment, Metastatic, Microsatellite, Instability-High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Cancer

Ervaxx and Cardiff University Collaborate to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens

Published: Jan 25, 2020 | Tags: Ervaxx, Cardiff University, Collaborate, Develop, Novel T-cell, T-cell, Receptor-based, Immunotherapeutics, Targeting, Dark Antigens

Incyte Reports Acceptance and Priority Review of BLA for Retifanlimab to Treat Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

Published: Jan 25, 2020 | Tags: Incyte, Reports, Acceptance, Priority Review, BLA, Retifanlimab, Treat, Patients, Squamous Cell Carcinoma, Anal Canal (SCAC)

Pfizer and BioNTech Signs an Agreement with Covax for Advance Purchase of Vaccine to Help Combat COVID-19

Published: Jan 25, 2020 | Tags: Pfizer, BioNTech, Signs, Agreement, Covax, Advance Purchase, Vaccine, Help, Combat, COVID-19

Aurinia Lupkynis (voclosporin) Receives US FDA's Approval to Treat Adult Patients with Active Lupus Nephritis

Published: Jan 25, 2020 | Tags: Aurinia, Lupkynis (voclosporin), Receives, US, FDA, Approval, Treat, Adult, Patients, Active, Lupus Nephritis

P&G Signs a License Agreement with Rhinostics to Launch its Novel Nasal Swab into the Market for Rapid COVID-19 Testing and Address Supply Shortages

Published: Jan 25, 2020 | Tags: P&G, Signs, License, Agreement, Rhinostics, Launch, Novel, Nasal Swab, Market, Rapid, COVID-19, Testing, Address, Supply, Shortages

Exelixis Cabometyx (cabozantinib) + Opdivo (nivolumab) Receives US FDA’s Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

Published: Jan 25, 2020 | Tags: Exelixis, Cabometyx (cabozantinib), Opdivo (nivolumab), Receives, US, FDA, Approval, 1L, Treatment, Patients, Advanced, Renal, Cell, Carcinoma

Related Post: PharmaShots Weekly Snapshots (Jan 18 - 22, 2021)